NV-5138 Drug Asset Due Diligence Report 2026

This NV-5138 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether NV-5138 can convert its Small molecule drug profile and mTORC1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	NV-5138 (query alias: NV-5138)
Modality / target	Small molecule drug; mTORC1; mTORC1 stimulants
Highest global status	Phase 2
Originator	Navitor Pharmaceuticals, Inc.
Active developers	Supernus Pharmaceuticals, Inc.

The MCP disease footprint includes Depressive Disorder, Treatment-Resistant. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05152680	Phase 1	Completed	6	Primary endpoint not disclosed in English source
NCT05066672	Phase 2	Completed	250	Primary endpoint not disclosed in English source
NCT03606395	Phase 1	Completed	80	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults With Treatment Resistant Depression

Phase 2; n=250; evaluation: Not stated in English source. Reported fields: Change From Baseline to Week 4 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score.(Mean) = -12.2 Unit ; Change From Baseline to Week 4 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score.(Mean) = -11.6 Unit

A novel, experimental design to assess rapid antidepressant action: Results from a phase 1b randomized trial of NV-5138

Phase 1; n=32; evaluation: Positive. Reported fields: AE = NV-5138 was well tolerated, with no psychotomimetic, severe, or serious adverse events reported.

An Open-Label, Single-Group Study to Evaluate the Efficacy and Safety of SPN-820 in Adults With Major Depressive Disorder

Phase 2; n=40; evaluation: Not stated in English source. Reported fields: Day 1 - 2 Hours(Mean) = -6.1 Point

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

NV-5138 addresses Depressive Disorder, Treatment-Resistant. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2020-04-21	Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138	Phase 1	US$25.0M upfront; US$475.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Mefluleucin for use in the treatment of suicidal ideations associated with depression”. The milestone feed surfaced a patent-application signal described as “MODULATORS OF mTORC1 ACTIVITY AND USES THEREOF”. The milestone feed surfaced a patent-application signal described as “Neuroactive steroids for treatment of CNS-related disorders”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO